

NXgenPort is a combination medical device plus software company harnessing the power of machine learning and remote patient monitoring for physicians to proactively manage at-risk cancer patients with an implanted Smart Port that detects early signs of infection and readiness for next treatment.

Founded: 2020

Website: NXgenPort.com Headquarters: St Paul, MN

Investment

\$2 M Seed Round (open) \$12M Series A (Q3:2024)

Use of Funds

Product Development & Validation Testing Intellectual Property & Patent Fees Engineering, Regulatory, Quality Hires Quality Management System Animal models Pre-submission to FDA Other Working Capital

Previous Investors

Baxter **Edward Elmhurst Ventures** Mavo Clinic Angels, HWI, F&F, Founders mHUB

Leadership



CATHY SKINNER Chief Executive Officer

Led three startups in oncology, focused on investor relations, and strategic partnerships



ROSANNE WELCHER, PHD, MBA Chief Operating Officer

+30 years in companion diagnostics and cancer, 50 products through FDA and 16 patents



KELLY CHRISTIAN, MS VP R&D Engineering

+30 years in med device development, 30 patents in ports



JOHN SLUMP **Board Chair** Serial entrepreneur, two exits for \$140M and \$800M

Contact

Cathy@NXgenPort.com 651-587-5440



Overview

NXgenPort is addressing an unmet need in cancer care by remotely monitoring patients between chemotherapy treatments with a Software as a Medical Device (SaMD) and an implanted Smart Port with intravascular cytometry sensors. By using machine learning to measure blood cell counts, vitals, and heart function in vivo, NXgenPort will alert physicians to early signs of infection, determine readiness for next treatment, and improve health equity and access. With the acceleration of Hospital at Home, care providers, cancer researchers, and pharma stakeholders find value in monitoring a patient's biological response to interventions with a robust data package to improve outcomes.

Highlights

- Built device prototype and tested it with human and swine blood
- Compared device results to a gold standard lab test
- Raised \$1.125M to date
- All IP owned by NXgenPort: Filed three patent applications one Utility (issued Q4:'23), one Utility (published), and one provisional
- Three years of a collaboration agreement with Mayo Clinic
- Completed Mayo Clinic Platform Accelerate [Aug 2023]
- Built, trained and tested model for predicting neutropenia risk
- Accepted to MedTech Innovator June 2023]
- Completed pre-clinical animal model testing [March 2023]
- Completed premier mHUB Accelerator in Chicago [May 2022]
- Verified existing CPT codes for reimbursement
- FDA strategy: Class II, 510(k) for hardware & software
- Beach-head market: early detection of neutropenia




Technology

- · Microelectronics with a power source in the body of the port and a fiber optic bundle through the wall of the catheter
- Autofluorescence illuminates the field and captures images of the blood cells as they flow by the fiber optic tip at the end of the catheter.
- Images are processed by a trained machine learning algorithm that counts the cells based on their known size and composition.
- Real-time, longitudinal data is analyzed and shared with physicians through an API to the electronic medical record so they can intervene before a problem escalates to hospitalization.

Competition

| | Ø NissenPort | Port Manufacturers | Wearables | Diagnostic Laboratories | Veris Health |
|--------------------------------------|---------------------|-----------------------|-----------|----------------------------|-----------------|
| Implanted device | ~ | ~ | | | ~ |
| Blood count measures | ~ | | | ~ | |
| Digital health platform | ~ | | ~ | | ~ |
| Oxygen, heart rate, body temperature | ~ | | ~ | | ~ |
| Novel data package | ~ | | | | |
| Passive data collection | ~ | | | | |
| In vivo blood count & heart function | ~ | | | | |

Market



receive a port and/or high risk, systemic therapy (oral targeted

25% of the market; +CMS new tech add-ons; managed services;

Collaborations









Timeline

| Milestone | Date | Cash Outlay |
|--------------------------------------|------------|--------------|
| FDA 510(k) Submission | 12/18/2025 | \$10,071,808 |
| Software as a Medical Device Release | 4/28/2026 | |
| FDA 510(k) Clearance | 8/6/2026 | \$13,281,894 |
| Production Ready | 10/13/2026 | |
| 1st Commercial Sale | 1/15/2027 | \$16,516,625 |
| Profitability | 4/1/2028 | \$25,771,962 |